HYPR
Hyperfine, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.72
−2.57%Year over year
Reported trailing growth
- Revenue
- +53.2%
- EBITDA
- +15.9%
- EBIT
- +20.4%
- EPS
- +26.4%
- Free cash flow
- +21.8%
- Operating cash flow
- +20.5%
Forward estimates
Based on analyst estimates
- Revenue
- +52.6%
- EBITDA
- +11.8%
- EPS
- +16.4%
Three-year CAGR
- Revenue
- +25.8%
- EBITDA
- +13.2%
- EBIT
- +14.2%
- Net income
- +12.6%
- EPS
- +23.2%
- Free cash flow
- +25.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026